Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look in the news section!!
I don't understand stand why people sell for cheap!! Same thing happens with HEMP that's happening here. This will shoot up very high soon GO ERBB
When do you think we make big jump up in PPS? In it for the long hall just want to see a nice spike north.
Seems to be working just fine
Yea, I just sold all my shares just broke even. Good luck to everyone
Why are they calling?
What do you think about CBIS & ERBB
Mixed Marijuana Messages from Trump Administration Make Diversification Imperative
Source: NetworkNewsWire
New York, New York (NetworkNewsWire) – Deciphering marijuana policy under the Trump Administration can be difficult, given differing statements by White House officials. Federal laws are at odds with a number of states that have legalized marijuana for medical and/or recreational use, and businesses like SinglePoint, Inc. (SING) (SING Profile), Corbus Pharmaceuticals Holdings, Inc. (CRBP), Medical Marijuana, Inc. (MJNA), Cannabis Science, Inc. (CBIS) and ChineseInvestors.com, Inc. (CIIX) (CIIX Profile) operate in a manner that hedges them against certain risks of federal prohibition.
On the campaign trail, then-candidate Donald Trump said of medical marijuana on Fox News: “I'm in favor of it a hundred percent.” With regard to the recreational use of marijuana, his stated preference was to leave it up to each state. At a briefing on February 23, however, Press Secretary Sean Spicer noted that President Trump sees “a big difference” between the use of marijuana for medical and recreational purposes, leaving many wondering about a federal crackdown.
Additionally, Attorney General Jeff Sessions on March 15, 2017, at a meeting of law enforcement personnel in Virginia, said: “I reject the idea that America will be a better place if marijuana is sold in every corner store. And I am astonished to hear people suggest that we can solve our heroin crisis by legalizing marijuana.”
The AG went on to say that marijuana was “only slightly less awful” than heroin, leaving cannabis companies that do touch the plant in limbo of what may come next. Particular defensive tactics vary, but most fall under a broad strategy of diversification and operations that involve servicing the broader industry by means of providing accessories, technological solutions, financial services and real estate, among others.
Case-in-point is SinglePoint, Inc. (SING) (SING Profile), a company that specializes in the acquisition of small to mid-sized companies. Through its wholly owned SingleSeed.com subsidiary, which several years ago geared up to offer payment-processing services to marijuana dispensaries, SinglePoint continues to explore ways to provide financial services to marijuana establishments.
The provision of payment services is part of SinglePoint’s “no-touch” strategy, an approach best demonstrated by its acquisition of a portion of Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Singlepoint recently announced it had closed the first round of funding for the acquisition (http://nnw.fm/oS8U5).
"We have evaluated numerous investment prospects in the cannabis space, and found there is nothing that compares to this opportunity we have with Convectium. With this transaction, we will acquire a stake in a cannabis business that never touches a marijuana plant. This is the strategy we will use as we move forward to hedge us against changing federal and state laws,” SinglePoint CEO Greg Lambrecht states in the press release.
Convectium has developed the world’s first oil-filling system for cartridges and disposable vape pens for wholesale distribution to dispensaries. The company’s 710Shark and 710Seal system can fill and package 100+ cartridges or disposable vape pens in 30 seconds, making it the fastest filling and sealing system of its kind. With a market that extends to over 52 countries, Convectium expects 2017 revenues to be about $3.5 million. This would represent an increase of 150 percent over 2016 revenues of $1.4 million.
The route taken by Corbus Pharmaceuticals Holdings (CRBP) is also likely to escape any cannabis clamp-down since the company is developing a synthetic drug that will be screened as it goes through the Food and Drug Administration (FDA) regulatory process. Its lead candidate, Anabasum, is a pioneering, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes, which is currently being evaluated in four phase II clinical trials. Endocannabinoid-mimetics are substances that stimulate the body’s natural production of cannabinoids. One of the most popular and widely used drugs for the treatment of pain and fever, called variously paracetamol or acetaminophen, is thought to work this way.
Also likely to be excluded from any crackdown on cannabis is Medical Marijuana (MJNA), which on its website states that its “operations in the federally legal hemp cannabidiol (CBD) market are unaffected by recent statements from Trump administration officials hinting at a crackdown on recreational marijuana. Medical Marijuana, Inc.’s hemp-based CBD products are unaffected by recreational laws or current political stances. The Company’s products are legal and if necessary will eventually be brought through the FDA approval process.” Medical Marijuana, it appears, focuses its operations to products derived from legal CBD hemp oil.
ChineseInvestors.com, Inc. (CIIX) (CIIX Profile) is also taking the high road with hemp. Late last month, the company announced it was launching the world's first CBD health products online store in the Chinese language under the domain name www.ChineseCBDoil.com. CIIX will use the site to sell CBD oil products to customers in Chinese mainland where hemp oil-derived products are legal and Chinese speakers in U.S. and Canada.
Another marijuana player is Cannabis Science (CBIS), which conducts research into cannabinoids to develop therapies for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders. Over 60 cannabinoids are to be found in cannabis. Some, like CBDs, are legal; others, like tetrahydrocannabinols (THC), are subject to various legal restrictions. Nevertheless, a broad-based cannabinoid platform seems likely to offer opportunities to shift strategy as the new administrations continues to huff and puff about marijuana.
For more information on Singlepoint, Inc. (SING) please visit: Singlepoint, Inc. (SING)
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Ok thank you
Just called Scottrade cannot get a hold of anybody, can anyone tell me why Scottrade will not allow me to buy MJMJ?
Does anyone know why you can't buy this stock on Scottrade?
For some reason Scottrade will not allow me to buy!! That really sucks
All this good news I don't know why it's a down day. Do you?
What does it mean
For PYCT to be a good investment I think they need to first get the house in order. By that I mean doing a RS to raise the stock value and that is just to start. IMO
Do u think Toyota will pull out if Michigan in the near future?
Takata Air Bag Recall Becomes Biggest Ever In US
Share this:More Sharing Services Share on facebook Share on twitter Share on email
0
DETROIT (AP/WWJ) – Under pressure from U.S. safety regulators, Takata Corp. has agreed to declare 33.8 million air bags defective, a move that will double the number of cars and trucks included in what is now the largest auto recall in U.S. history.
The chemical that inflates the air bag can explode with too much force, blowing apart a metal inflator and sending shrapnel into the passenger compartment. The faulty inflators are responsible for six deaths and more than 100 injuries worldwide.
“One congressman even likened it to driving down the road with a shotgun pointed at your face,” said WWJ Automotive Analyst John McElroy. “It’s killed a number of people, it’s extremely tragic, it’s very dangerous.”
The announcement was made Tuesday afternoon by the heads of the Department of Transportation and the National Highway Traffic Safety Administration, which reached an agreement with Takata after sparring with the company for the past year over the size of the recalls and the cause of the problem.
Eleven automakers, including Honda Motor Co. and Toyota Motor Corp., have recalled 17 million vehicles in the U.S. and more than 36 million worldwide because of the problem.
McElroy said the recall will begin in humid states and is expected to take over a year. It’s unclear which manufacturers will be most affected by the expansion of the recall.
The Takata air bag recall dwarfs last year’s highly publicized recall of 2.6 million General Motors small cars for defective ignition switches and Toyota’s recalls of 10 million vehicles for problems with unintended acceleration.
“No one can figure out why these things are failing!” McElroy said. “So, even though Takata is saying, sure, bring these things back, we’ll replace them — and the new ones are fine —they said that the old ones were fine. So I can understand why Takata has not exactly rushed into these recall.”
NHTSA Administrator Mark Rosekind said investigations by the agency and auto industry haven’t determined precisely what’s causing Takata’s inflators to explode, but said the agency cannot wait for a cause to take action.
“We know that owners are worried about their safety and the safety of their families,” he said. “This is probably the most complex consumer safety recall in U.S. history.”
He said people who get recall notices in the mail should immediately make an appointment to get their cars fixed.
What about the ongoing problem with vehicle owners disregarding recalls?
“There’s a lot of people who just ignore them, but this is a little bit different,” McElroy said. “When you know that that air bag could go off, totally unexpectedly — and especially shoot, literally, shrapnel into your face that could kill you — I think they’re going to get a lot more people bringing their cars in with this recall.”
TM and © Copyright 2015 CBS Radio Inc. and its relevant subsidiaries. CBS RADIO and EYE Logo TM and Copyright 2015 CBS Broadcasting Inc. Used under license. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the closing of its previously announced underwritten public offering of 24,358,974 shares of common stock, and warrants to purchase an aggregate of 12,179,487 shares of common stock at an exercise price of $2.08 per share. The underwriters also exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,826,923 shares of common stock. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
The net proceeds to Galena are expected to be approximately $35.4 million, assuming no exercise of the warrants and after deducting underwriting discounts and commissions and estimated offering expenses payable by Galena.
We should see a very nice spike
Galena Biopharma (GALE -17.3%) prices its public offering of 24,358,974 units at $1.56 per unit. Each unit consists of one share of common stock and a warrant to purchase one half of a share of common stock at an exercise price of $2.08. Underwriters over-allotment is an additional 3,653,846 shares of stock and warrants to purchase up to 1,826,923 shares. Closing date is March 18.
Hope this bounce back for now I'm sitting on the sidelines sold out on 3/13/15 looking to see what will happen this could be a bad move on my part if no bankruptcy is filled, but we will see
Divergent monetary policy paths between the U.S. and the Eurozone, oil prices touching 6-year lows, and speculation surrounding when the Federal Reserve will tighten its monetary policy are rife in the markets, bringing in fresh bouts of volatility every day. Such volatility usually translates into frenzied trades by investors, as every little movement in a company seems to have huge implications for its future. Well, this is not necessarily so.
Time and again, the herd mentality of investors comes into play and they dump a beaten down stock simply because that seems to be the common trend. However, investors should take a hard look at whether the market has exaggerated the bad developments of a company before dismissing these beaten-down stocks.
For instance, certain stocks trading near their 52-week lows are, at times, windows of opportunity for patient investors, and offer huge return potential. Here we offer three such stocks that have been out of favor with investors lately, but have promising future prospects coupled with a great Zacks Rank.
3 Beaten Down Stocks to Buy Now
These stocks have tumbled over the past due to an assortment of reasons, be it company-specific or macroeconomic, and stand in sharp contrast to the S&P 500’s 11.5% gain over the same time frame. However, these companies’ fundamentals and future prospects still shine bright, and the low valuation serves as the perfect opportunity for investors to jump in and ride the anticipated growth. And to top it off, all these stocks sport a solid Zacks Rank, thus we recommend buying these angels who seem to have fallen from grace.
Galena Biopharma, Inc. (GALE)
Shares of this biopharmaceutical company, which specializes in developing and commercializing oncology drugs, have tumbled nearly 55% over the past year, following allegations that the company was paying a marketing firm called The DreamTeam Group to pump its stock. Company insiders made millions of dollars by selling company shares during that period, and the biotech company is still under active SEC investigation.
However, since then, the company has moved mountains in order to distance itself from its scandalous past. In a drastic change, nearly half of Galena’s management has been replaced with industry veterans. Also, the company still has an impressive product pipeline and is seeing significant advancements in its promising new drug NeuVax, which is used to prevent recurring cancers in survivors. Also, its products Abstral and Zuplenz are showing robust performance.
We believe that the shares are undervalued at present, and that despite the scandal, the essential science behind the business remains intact, making it a worthwhile investment.
The stock has been seeing positive estimate revision activity over the past month, as the current year loss consensus estimate has narrowed 2.9% over the same time frame.
Current Price: $1.42
52 Week Low: $1.33
Zacks Rank #2 (Buy)
Africa Oil Corp. (AOIFF)
The oil and gas exploration and development company has lost 79.7% in the past year, as oil prices continue to plummet on oversupply concerns. However, the company has a number of short-term growth drivers at present.
The company has made several oil discoveries in recent times, which never got factored in the share price. It has 13 basins open for exploration in the coming 18 months, which can prove to be a strong boost for the company’s stock price. The East Africa oil exploration industry is an emerging market, and efforts are underway to resolve infrastructure issues and make way for exports to international markets.
Moreover, the sustained weakness in oil prices is actually a reason to go on the offensive in the industry. It’s doubtful that oil and natural gas prices will continue their trend for an extended period of time, hence any bounce back would represent a catalyst for this space.
The stock has been seeing positive estimate revision activity over the past month, as the current year loss consensus estimate has narrowed 17.6% over the same time frame.
Current Price: $1.59
52 Week Low: $1.54
Zacks Rank #2 (Buy)
CTI BioPharma Corp. (CTIC)
It's A Good Time To Save. Get A Quote From Geico!
GEICO Sponsor
?
The biopharmaceutical company is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company faced a massive rush of sellers after it released its fourth-quarter and full-year 2014 earnings results last week, and shares have tumbled nearly 5% since then. The stock has shed 49.4% of its value over the past year.
The company recently entered into a global development and commercialization collaboration for its product PIXUVRI. There has been some uncertainty surrounding its Phase 3 PERSIST-1 study assessing pacritinib in patients with primary or secondary myelofibrosis, a rare cancer of the bone marrow. However, the FDA granted pacritinib fast-track designation some time back, which could translate into a speedier evaluation.
The stock has been seeing positive estimate revision activity over the past couple of months, with the current year loss consensus estimate narrowing 11.8% over the same time frame.
Current Price: $1.97
52 Week Low: $1.93
Zacks Rank #2 (Buy)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CTI BIOPHARMA (CTIC): Get Free Report
GALENA BIOPHARM (GALE): Get Free Report
AFRICA OIL CORP (AOIFF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
NEW YORK (TheStreet) -- Shares of Mechel OAO (MTL) are falling by 30.19% to $1.08 on heavy volume in mid-afternoon trading on Monday, as the Russia-based integrated mining and steel company may reportedly go bankrupt, according to Motley Fool.
Russian Economic Minister Alexei Ulyukayev said bankruptcy was "inevitable" for the company following the failure of talks regarding the restructuring of Mechel's $6 billion in debt, however, there is no guarantee that Mechel will end up going bankrupt, Motel Fool said.
Sanctions from the U.S., a decline in the ruble, increased debt, and a weak commodity environment all contributed to Mechel's precarious financial situation.
Mechel has been dealing with a volatile year. Last October the company was warned by the NYSE that its American Depository Receipts were no longer in agreement with the listing norms, however earlier this month the company announced that its ADRs are in agreement with listing norms, Zacks Equity Research reported.
In February, Mechel sold several mining sites and processing plants in West Virginia for $5 million to the family of businessman Jim Justice, Bloomberg reported. Mechel is in line to receive royalty payments of 12.5% of any future sale of Bluestone Resources within five years, and 10% within the following five years.
MTL data by YCharts
Home
New Posts
Popular
Kenneth Rapoza, Contributor
I cover business and investing in emerging markets. FULL BIO
INVESTING 3/14/2015 @ 7:46PM |52,298 views
Russian Billionaire Oligarch Faces Bankruptcy
Share 7 Comments
Russian mining giant Mechel is going bye-bye. And that’s going to hurt one very wealthy oligarch.
Economic Minister Alexei Ulyukayev said Friday that the debt-ridden Mechel’s bankruptcy was now “inevitable”. Mechel is Russia’s leading coal producer.
Ulyukayev told reporters in Egypt that attempts to restructure Mechel’s $6 billion debt had failed. He said Mechel was unable to find a white-knight to buy the company. “Unfortunately, the recent developments clearly show that no other options but bankruptcy are left,” Ulyukayev said.
Mechel shares have collapsed since the end of the commodity super cycle in 2010. Shares of the company’s American Depositary Receipts are down 94% in the last five years. Last October, the NYSE told the company that it will be delisted if the stock trades under $1 a share for a 30 day period. The stock is currently $1.54 with fairly high volume and was removed from the warning list on March 2.
But like most Russian securities, it’s currently being used as a gambling chip by hedgies and day traders. Some short-termers have made a lot of money off this coal miner. It’s up over 125% year-to-date and continues to trade over its 200 day moving average.
Russia’s state owned VTB Bank and Sberbank will be left holding the bag for this one should it go belly up.
Mechel was born 12 years ago, late in the commodity boom. FORBES billionaire Igor Vladimirovich Zyuzin is the Russian oligarch behind the company, owning over half of Mechel’s shares. Zyuzin has mining operations in 11 Russian states, and while coal is his biggest source of wealth, he also sells iron ore and runs some coal-fired power plants. Mechel is home to roughly 80,000 employees, making it an important asset for the government to try and save despite Zyuzin not being one of Vladimir Putin’s preferred businessmen.
Mechel can be delisted if it trades under $1 a share for 30 days. Day traders and hedge funds are having fun keeping the stock alive. Mechel is up triple digits in the last three months.
Russia’s economy is going through tough times. Western sanctions due to Russian involvement in the Ukraine separatist movement, coupled with low oil prices have led economists to forecast a contraction in Russian GDP this year.
Mechel might still find a buyer. The problem is political risk. Sanctions will make doing business in Russia difficult for Western firms to find it attractive.
In the U.S., Mechel recently sold its Mechel Bluestone, Inc. for a mere $5 million to a small, coal mining family business from West Virginia.
Only 9million left at .0001
Buy the last .0001 and get this thing roiling only 9 million left
Only 9 million left at .0001
Now is the time to buy
HONG KONG, CHINA--(Marketwired - November 03, 2014) - PayChest, Inc. (PYCT)
PayChest is pleased to announce that the Company, with its partners, have completed the design of its first flushable and biodegradable adult protection product.
This first product in PayChest's adult protection range is for light adult protection and will target the expanding "50 years or more" consumer market typified by baby boomers. Around one person in six that is 50 years or more uses some form of adult protection. Consumers typically use these light adult protection products to protect against urinary leaks caused by factors such as childbirth, diabetes, prostate problems, certain prescribed medicines and age related muscle control issues.
The superior discretion offered by a flushable adult protection product allows the consumer -- male and female -- to preserve their dignity and image of living a healthy and active lifestyle.
This new product draws on patents and designs currently owned or licensed by PayChest.
Together, the flushable and biodegradable adult protection range with the Mibella®/Flushaway® biodegradable and flushable womens sanitary product range provide the Company greater revenue potential, additional product lines and ultimately better revenue protection.
The Company expects to have prototypes available during the first quarter 2015, provided by Xinpro, our production partner that also manufactures the Mibella®/Flushaway® womens sanitary product range.
As more information comes available regarding the new product line, and any other developments, the Company will deliver this information to the market by news release. Those not currently on our e-mail list for news releases are encouraged to call or e-mail the company to be added.
NOTES ABOUT FORWARD-LOOKING STATEMENTS
Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company's filings with OTC Markets http://www.otcmarkets.com/stock/PYCT/financials.
Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made.
Historical news releases on the Company can be found at http://www.paychest.com/news.htm.
EDISON EQUITY RESEARCH - ACTINIUM PHARMACEUTICALS
Source: InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ACTINIUM PHARMACEUTICALS - PUBLIC OFFERING TO FUND LATE-STAGE DEVELOPMENT
Actinium Pharmaceuticals is developing targeted radiation therapies (both a- and ß-particle based) that offer the prospect of highly selective tumour cell killing with limited side effects compared to existing therapies. The underwritten public offering consists of 4.44m shares and 3.33m warrants (exercisable over four years) at a combined price of $4.50. The $20m (gross) raised will be used to progress the late-stage clinical programmes to key value inflection points, notably Iomab-B in a pivotal Phase III trial.
Actinium Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops drugs for the treatment of various cancers. Actimab-A is in Phase I/II clinical trials for acute myeloid leukaemia. Iomab-B is entering Phase II/III trials for myeloconditioning for hematopoietic stem cell transplantation.
To view our full report, please click here
Click here to view all of Edison Investment Research’s published reports
Buy the near 20 million shares and let's get started
No I don't keep changing, it is a small order 6,250,000 @ .0001
Why are my shares in which I have had for sale now for about 30 days now, have not sold? Is it because of scottrade?
Please buy all the .0001 then and get this kicked started
.0001
Please buy my 6250000 shares I'm trying to sell for the last three months.
PayChest Completes Designs for New Flushable & Biodegradable Adult Incontinence Product
Marketwired PayChest, Inc. 4 hours ago
HONG KONG, CHINA--(Marketwired - November 03, 2014) - PayChest, Inc. (PYCT)
PayChest is pleased to announce that the Company, with its partners, have completed the design of its first flushable and biodegradable adult protection product.
This first product in PayChest's adult protection range is for light adult protection and will target the expanding "50 years or more" consumer market typified by baby boomers. Around one person in six that is 50 years or more uses some form of adult protection. Consumers typically use these light adult protection products to protect against urinary leaks caused by factors such as childbirth, diabetes, prostate problems, certain prescribed medicines and age related muscle control issues.
The superior discretion offered by a flushable adult protection product allows the consumer -- male and female -- to preserve their dignity and image of living a healthy and active lifestyle.
This new product draws on patents and designs currently owned or licensed by PayChest.
Together, the flushable and biodegradable adult protection range with the Mibella®/Flushaway® biodegradable and flushable womens sanitary product range provide the Company greater revenue potential, additional product lines and ultimately better revenue protection.
The Company expects to have prototypes available during the first quarter 2015, provided by Xinpro, our production partner that also manufactures the Mibella®/Flushaway® womens sanitary product range.
As more information comes available regarding the new product line, and any other developments, the Company will deliver this information to the market by news release. Those not currently on our e-mail list for news releases are encouraged to call or e-mail the company to be added.
NOTES ABOUT FORWARD-LOOKING STATEMENTS
Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company's filings with OTC Markets http://www.otcmarkets.com/stock/PYCT/financials.
Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made.
Historical news releases on the Company can be found at http://www.paychest.com/news.htm.
Contact:
Paychest, Inc.
ir@paychest.com
Tom Hands:
1-416-619-5242
1-302-724-6944
SMNG .0003 today?
HONG KONG / ACCESSWIRE / October 17, 2014 / Paychest, Inc. (PYCT) PayChest Inc. is pleased to announce the buyback of 100 million shares and completion of its buyback and stock retirement program as previously announced.
This 100 million shares is the last part of 300 million shares repurchased by the Company. The outstanding share count, confirmed with the Company transfer agent, Transfer Online, is reduced to 27.685 billion shares giving the Company a present market cap of approximately $2.7 million.
Over $7 million has been spent to date developing the Mibella/Flushaway(R) brand of flushable and biodegradable women’s sanitary liners and pads. The first container of product is slated to be ready for delivery in the first quarter 2015 as part of the $1.2 million purchase order provided by David Shaw and Co., the Company's UK distributor. Each container of product equates to about $50,000 US revenue to Paychest.
The Company is now opening talks with new distributors in the US and other countries in readiness of product availability.
Unlike competing products sold by the major companies, such as Proctor & Gamble, Kimberly-Clark and Johnson & Johnson, the Mibella/Flushaway(R) product line is flushable and biodegradable while remaining price competitive.
NOTES ABOUT FORWARD-LOOKING STATEMENTS
Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company's filings with OTC Markets http://www.otcmarkets.com/stock/PYCT/financials.
Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made.
Contact:
Paychest, Inc.
PayChest Updates $1.2 Million Purchase Order
HONG KONG / ACCESSWIRE / October 3rd, 2014 / Paychest, Inc. (PYCT) (the "Company") is providing an update on the previously announced $1.2 million purchase order with its UK agent, David Shaw & Co.
Over recent months PayChest has held extensive meetings with Xinpro Manufacturing film division and sanitary products manufacturing to prepare for production. Significant progress has been made and the Company anticipates first containers of product will be ready for delivery to David Shaw & Co. in the first quarter of 2015.
The company will sell its Mibella(R) product range, a patented and trademarked brand of flushable and biodegradable women's sanitary pads and liners into the UK and the US. The Company has also received strong interest from distributors and wholesalers interested in selling Mibella(R) products in mainland Europe, Asia and Africa. Each container generates revenue of around US$50,000 for PayChest, depending on product mix.
Mibella(R) offers consumers more features for the same price as competing products from the market leaders. Competing products in this fast moving consumer goods market, produced by Proctor and Gamble, Kimberly-Clarke and Johnson & Johnson, are neither flushable nor biodegradable.
Consumer and retailer acceptance of our flushable and biodegradable product is already proven.
The Company’s UK Mibella(R) trademark (UK00002602822) is registered until 2021 and can be viewed at www.ipo.gov.uk. Mibella(R) trademarks in other jurisdictions are being prepared and/or filed.
NOTES ABOUT FORWARD-LOOKING STATEMENTS
Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company's filings with OTC Markets http://www.otcmarkets.com/stock/PYCT/financials.
Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made.
Contact:
Paychest, Inc.
ir@paychest.com
Tom Hands
USA 302-724-6944
from overseas: +1-302-724-6944
Canada 416-619-5242
from overseas: +1-416-619-5242
Historical news releases on the Company can be found at http://www.paychest.com/news.htm.
SOURCE: PayChest, Inc.
Best of luck to everyone
Yahoo Finance
Vision Industries Files for Voluntary Chapter 11 Bankruptcy Protection
Accesswire Sep 25, 2014 5:00 PM
Long Beach, CA / ACCESSWIRE / September 25, 2014 / Vision Industries Corp. (VIIC) today announced that the Company has voluntarily filed for Chapter 11 bankruptcy protection. This event was primarily the result of its inability to obtain quorum at its August 22, 2014, Shareholder Meeting, at which the Company sought permission to increase its authorized share count from 500 million to 10 billion common shares. The increase in authorized shares was requested by management to enable the Company to seek further funding to continue operations.
"We are disappointed by the lack of participation by our shareholders, especially by our main shareholder. This more than limited our options to raise capital; it effectively made it impossible," says Vision's CEO Martin Schuermann.
During the reorganization process, Vision will continue to operate and work on ongoing government supported programs and R&D projects. It is the Company's intention to reemerge from the Chapter 11 protection with a healthier balance sheet and thus be able to raise capital to execute its business plan.
About Vision Industries
Vision is a developer of zero emission hydrogen fuel cell-electric powered vehicles and turnkey hydrogen fueling systems. Vision's proprietary fuel cell-electric hybrid drive system combines the superior acceleration of a battery powered electric vehicle with the extended range provided by a hydrogen fuel cell. For more information on Vision Industries Corp., please visit www.visionindustriescorp.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors available from the Company.
###
Contact:
Investor Relations
IR@visionmotorcorp.com
310-454-5658
SOURCE: Vision Industries Corp.